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Abstract
Background: Breast cancer is a heterogeneous and a hormone-dependent disease. The detection of the estrogen
receptor (ER) and progesterone receptor (PgR) is crucial for prognostic evaluation and treatment choice of breast
cancer for clinical practice. The purpose of this study was to evaluate the expression of the hormonal receptors,
their distribution, and their correlation with clinicopathologic prognostic parameters for the improvement of the
patients’ treatment in Ivory Coast.
Methods: The 20-month prospective study included 302 patients who were diagnosed with primary invasive breast
carcinomas at the Central Laboratory in Abidjan. The paraffin-embedded blocks of these patients were examined by
immunohistochemistry to assess the ER and PgR status. The one-way analysis of variance and Chi-Square Test were
used to analyze the data.
Results: The mean age of patients at diagnosis was 48 ± 11 years. The majority of the women were premenopausal
in 180 cases (59.9%). The predominant histologic type was invasive ductal carcinoma not otherwise specified (IDC
NOS) in 247 cases (82%). Tumor grade 2 was more frequent in 166 cases (55%). Among 302 patients, 169 (56%) and
154 (49%) expressed ER and PgR respectively. The ER+PgR+ group with 131 cases (43%) was predominant, followed
by 116 cases (38%) of ER-PgR-. The expression of ER and PgR was correlated with the age of the patients (p = 0.026)
and the tumor grade (p = 0.0004). However, there was not statistically significant correlation between ER/PgR and
the menopausal status of patients (p = 0.149), nor between ER/PgR and the histologic type (p = 0.523).
Conclusion: The ER+PgR+ and ER-PgR- are the most common subgroups in women with breast cancer in Ivory
Coast. The hormonal receptor status is associated with the age and the histologic grade in breast cancer patients.
The systematic use of hormonal treatment should be reevaluated. A further study should be done to investigate
the reasons of high rate of ER-PgR- in breast cancer patients in Ivory Coast.
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Background
Breast cancer is the most frequent malignant tumor and
the most common cause of cancer-related death among
women in the developed countries [1, 2]. Breast cancer is
increasing in the developing countries, including Ivory
Coast, where it ranks at the first cancer in women after
cervical cancer [3]. Breast cancer is a hormone-dependent
disease, and thus, resulting from the mitogenic effects of
estrogen and progesterone [4, 5]. The positivity of the ER
is generally more than 70% in women with breast cancer
than that of PgR, 50% [6, 7]. The ER/PgR status is essential
for clinical and therapeutic care of the breast cancer pa-
tients [8, 9]. The ER has well-established prognostic and
predictive values [9, 10], while the PgR has a controversial
additional predictive value [11, 12]. The presence or not of
ER and PgR helps determine a possible relapse of breast
cancer [9]. The hormonal receptor status allows to distin-
guish four subgroups of breast cancers: ER+PgR+, ER
+PgR-, ER-PgR+, and ER-PgR- [8, 13, 14]. This classifica-
tion helps to decide hormonal treatment for ER/PgR posi-
tive patients and chemotherapy for the ER/PgR negative
patients [9, 15]. Although the immunohistochemical
evaluation of ER and PgR is a routine clinical practice in
the diagnosis and treatment of breast cancer management
worldwide, the clinical utility of ER and PgR testing in
breast cancer is currently performed since June 2013 in
Ivory Coast. Moreover, very few studies have been done
on small sample size (22 patients) to assess the hormonal
receptor status of breast cancer in Ivory Coast [16]. The
current research is essential to update the immunohisto-
chemical activity of ER/PgR in primary breast cancers.
Herein, the aim of this study was to evaluate the expres-
sion of ER and PgR, their distribution, and their correl-
ation with classic clinicopathologic prognostic parameters
(age, menopausal status, histologic type, and grade) to
enhance the breast cancer patients’ medical care. The
present study will contribute to classify patients into
different subgroups based on their hormonal receptor sta-
tus in order to determine the better treatment strategies
for women with breast cancer in Ivory Coast.
Methods
Patients
The prospective study was conducted between November
2013 and June 2015, including 302 patients diagnosed
with primary invasive breast carcinomas at the Central
Laboratory in Abidjan, Ivory Coast. The histologic diagno-
sis was performed upon paraffin-embedded breast tissue
blocks sampled from 261 (86.4%) needle core biopsies and
41 (13.6%) mastectomies. On each sample, the histologic
type and the Nottingham grade of the tumor were deter-
mined according to the criteria of Elston and Ellis [17].
The parameters of the study were classic clinicopathologic
parameters (age, menopausal status, histological type, and
tumor grade) and the status of ER and PgR. Paraffin-
embedded blocks of breast tissue were subjected to the
immunohistochemical assessment.
ER/PgR immunohistochemical analysis
The immunohistochemical analysis was performed on
3 μm thickness of breast tissue sections. Tissue sections
were deparaffinized and heated in the drying oven
BINDER ® (BINDER Company, Tuttlingen, Germany) for
at least 12 h at 600 C to unmask the antigenic sites. The
sections were stained using the Ventana BenchMark ®
GX in automatic mode (Ventana Medical Systems Inc.,
Tucson, AZ, USA) for the assessment of ER and PgR
status. The antibody clones were monoclonal, developed
in rats, consisted of SP1 for the ER and 1E2 for the PgR,
and manufactured by Ventana Medical Systems, Inc.
Staining assessment of ER/PgR
The visual analysis through the optic microscope
allowed to evaluate the staining intensity (weak, moder-
ate, intense) and the percentage of tumor cells showing
a nuclear immunostaining for ER and PgR (range: 0-
100%). Breast tissue sections were considered positive
for the ER and PgR if ≥ 1% of tumor cells displayed a
positive nuclear staining in accordance with the
recommendations of the American Society of Clinical
Oncology/College of American Pathologists [18]. The
immunostaining intensity and the percentages of stained
cells for ER and PgR were reviewed independently by
two pathologists. For the purpose of this study, the per-
centages of tumor cell nuclei positively stained for ER
and PgR were considered.
Statistical analysis
Data were collected in an Excel database from Windows
8 (Microsoft Corporation, Redmond, WA, USA). The
difference between the subgroups based on the status of
ER/PgR and the mean age were evaluated by the one-
way analysis of variance. The Chi-Square Test was used
to analyze associations between classic clinicopathologic
parameters (menopausal status, histological type, and
tumor grade) and combined ER/PgR status. A p-value <
0.05 was considered statistically significant. The data
were reported as frequencies for menopausal status,




The mean age of patients at diagnosis was 48 ± 11 years
(extremes: 24–84 years). The clinicopathologic charac-
teristics in breast cancer patients are shown in the
Table 1. Among 302 patients, 180 cases (59.9%) were
premenopausal patients compared to 112 cases (37.1%)
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of postmenopausal patients. The frequent histological
type was IDC NOS with 247 cases (82%). Of these can-
cers, 41 (13.6%) were grade 1; 166 (55%) were grade 2;
and 63 (20.9%) were grade 3.
Hormonal expression of ER and PgR
The Table 2 summarizes the combined ER/PgR status.
ER and PgR positivity was 169 cases (56%) and 148 cases
(50%) respectively. Almost half (131 cases; 43%) of the
women in this study expressed both ER and PgR,
followed by 116 cases (38%) in ER-PgR- patients.
Association of ER/PgR status with classic clinicopathologic
parameters
A significant relationship was found between the ER/
PgR status and the age of patients (p = 0.026); and be-
tween the ER/PgR status and the tumor grade of breast
cancer (p = 0.0004), while the correlations of the ER/PgR
status with the menopausal status (p = 0.149) and with
the histologic type (p = 0,523) were not statistically sig-
nificant (Table 3).
Discussion
For decades, samples of patients diagnosed with invasive
breast carcinomas were sent to laboratories equipped
with immunohistochemical techniques in the developed
countries for ER and PgR examination. The Roche-
Hoffman Laboratory in Ivory Coast, in collaboration
with the Ivorian Health Ministry, has recently offered a
Unit of Immunohistochemistry to the Central Labora-
tory to investigate the ER/PgR status of breast cancer
patients for an efficient medical support. This study
aimed at determining the hormonal receptor status to
better characterize breast cancer subtypes and to assess
the association of the hormonal receptor with age,
menopausal status, histologic type, and tumor grade.
In the present study, several significant observations
have been identified. The mean age of all patients at the
diagnostic was 48 years, indicating that breast cancer ap-
pears early, before the menopause. This finding is similar
to several studies conducted in Africa [16, 19–22] and in
the Middle East [23]. However, the mean age of our
patients is different from that of the developed countries
[2, 6, 24], where breast cancer commonly occurs at the ad-
vanced age or at the postmenopausal period. The early oc-
currence of breast cancer in women in Ivory Coast could
be due to the relative short life expectancy (54 years), the
multiparity, and the early age at first childbirth. Parkin et
al. found that the multiparity increased the risk of breast
cancer before 45 years in a study in Zimbabwe [25]. More-
over, the multiparity [26, 27] and the early age at first
childbirth [28] were the main risk factors for breast cancer
in black American women. These observations may
explain the high incidence of the breast cancer in premen-
opausal patients in our study.
In this study, IDC NOS associated with tumor grade 2
was predominant. These results are in agreement with
data of other studies [7, 29], suggesting that clinical
prognostic factors of breast cancer are worse in the Afri-
can women, including Ivorian women. In contrast, the
histologic type and the tumor grade have insufficient
prognostic and predictive implications with limited clin-
ical utility [30]. Therefore, it is valuable to detect ER and
PgR status immunohistochemically in the current study
to evaluate the survival of patients and to select their
treatment.
The proportion of patients expressing ER is superior
to those of PgR+. The same finding was reported by dif-
ferent authors in Europe, [29, 31, 32], in the USA [7, 8],
and in Africa [21, 33]. In addition, ER+PgR+ and ER-
PgR- were the most frequent subtypes in the current
study. Our remarks corroborate with results of several
studies [8, 13, 27, 33], suggesting that ER+PgR+ patients




Premenopausal (<50 years) 180 (59.6)
Postmenopausal (≥50 years) 112 (37.1)
Histologic type








Table 2 Distribution of ER/PgR in breast cancer patients
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should be considered for hormonal therapy, and ER-
PgR- patients should benefit from chemotherapy. Previ-
ously, a large number of breast cancer women under-
went a systematic hormonal treatment in a blind manner
in Ivory Coast. However, 38% of the study patients may
not suitable for hormonal therapy, tamoxifen, since they
do not express ER and PgR. As a result, they will not
benefit from hormonal therapy, and the chemotherapy re-
mains the only systematic treatment [9, 34, 35]. In this
study, ER+PgR+ patients would more favorably respond
to hormonal therapy than ER+PgR- and ER-PgR+ patients
[9, 14, 36]. Additionally, ER+PgR+ patients, receiving hor-
monal therapy, have the advantage of avoiding a tumor re-
lapse leading to a good long-term survival [9].
The high rate of ER-PgR- in our study is a remarkable
finding and is approximately comparable with results re-
ported by Seshie et al. in Ghana [37], Galukande et al. in
Uganda [38], Adeniji et al. in Nigeria [39], and Palmer et
al. in black American women [27]. Palmer et al. identi-
fied that the ER-PgR- subtype is greatly aggressive and
resistant to hormonal therapy whose incidence is in-
creased in the black American population. This high rate
is related to the multiparity [27] and the early age at first
childbirth [28]. Further studies should be done to deter-
mine the inherent reasons of the large frequency of ER-
PgR- patients in Ivory Coast. Additionally, the increased
proportion of ER-PgR- subtype could be explained by a
deficiency of the preanalytical factors, particularly the
fixation quality, investigated by Werner et al. [40] and
Goldstein et al. [41]. Hence, a multidisciplinary collabor-
ation between oncologists, radiologists, and pathologists
is required to have sampled breast tissues fixed within
the allotted time (6–18 h) to preserve hormonal receptor
epitopes [40, 41].
In this current study, the ER-PgR+ subtype, accounting
for 6%, is identical to that reported by Osborne et al. [8]
and Hefti et al. [13]; however, differ from that of Nadji et
al. [7] and Inwald et al. [32], who listed 0% and 0.8% re-
spectively. Hefti et al. [13] have recently found that ER-
PgR+ group does not represent a subtype of biologically
distinct or clinically important cancer, and therefore,
should be regarded as a false negative. This artifact
subtype results from an inappropriate fixation leading to
the loss of epitopes of paraffin-embedded breast tissue
blocks [7, 40, 41].
Despite the unquestionable contribution of ER and
PgR testing for a better therapeutic implication, it ap-
pears necessary to examine the correlation between ER/
PgR status with standard clinicopathologic parameters of
primary invasive carcinomas in 302 patients. There was
a significant association between the age of the patients
and the ER/PgR subgroups. The ER/PgR status has no
significant influence on the menopausal status. Our re-
sults are consistent with findings of Elwood and Godol-
phin. Both authors revealed in an analysis of multiple
regression study of age and menopausal status in 735 pa-
tients that the mean age was significantly associated with
the ER/PgR, while there was no significant link between
the ER/PgR and the menopausal status [6]. In the past,
tamoxifen was given based on the menopausal status of
patients in Ivory Coast because postmenopausal patients
appeared to be ER+PgR+ and would better respond to
tamoxifen than premenopausal patients. As a result, our
data pinpoint that hormonal therapy should be given re-
gardless of the menopausal status.
A correlation was found between the ER/PgR and the
tumor grade, which corroborates with the literature data
[6, 7]. In contrast, there was not significant association
Table 3 Relationship between ER/PgR with age, menopausal status, histologic type, and grade in breast cancer patients
ER+PgR+ (N = 131) ER+PgR- (N = 38) ER-PgR- (N = 116) ER-PgR+ (N = 17) p value
Age p = 0.026
Mean (± SD) 46 (±11) 49,05 (±9.20) 49 (±10.92) 53 (±10.20)
Extreme 24-83 33-72 27-84 34-74
Menopausal status χ2 = 6.1 p = 0.175
Premenopause 88 23 61 8
Postmenopause 40 14 49 9
Histologic type χ2 = 5.2 p = 0.523
IDC NOS 104 29 100 14
Lobular 8 1 3 1
Other 12 6 8 2
Tumor grade χ2 = 18.9 p = 0.0004
1 26 5 10 0
2 73 22 59 12
3 20 4 36 3
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between ER/PgR status and the histologic type. This re-
sult differs from finding of numerous studies [6, 7, 34].
Nadji et al. observed that ER status predicted some
histologic types in breast cancer, and thereby, a lack of
such correlation in our study should suspect a technical
problem [7]. In our study, this technical problem may be
resulted from the morphologic diagnostic errors or the
handling issue of preanalytical factors of breast samples,
such as the duration and the type of fixation.
Conclusions
The ER+PgR+ and ER-PgR- are the most common sub-
types and occur in premenopausal women. The hormo-
nal receptor status is associated with the age and the
tumor grade in breast cancer patients. Taken together,
the results of this study help to eliminate a systematic
use of hormonal therapy based on the menopausal status
of the breast cancer patients. The increased proportion
of ER-PgR- patients needs to be carefully considered in a
future study. The ER/PgR status is no longer sufficient
to treat breast cancer patients in Ivory Coast since the
human epidermal growth factor receptor 2 (Her2) over-
expression analysis and the Ki67 index are required to
define the molecular classification of breast cancers for
better treatment strategies.
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